Raza Ur Rehman on Fitusiran as a First-in-Class RNAi Therapy in Hemophilia A and B
Raza Ur Rehman, Bachelor of Medicine and Surgery at Shaikh Khalifa bin Zayed Al Nahyan Medical and Dental College, shared on LinkedIn:
”Publication Alert
Thrilled to share that our Open Access commentary has been published in Health science Reports (Wiley )
Rebalancing Hemostasis: Fitusiran as a First-in-Class RNAi Therapy in Hemophilia A and B
Health Science Reports | Volume 9, Issue 1
(e71702)
Raza Ur Rehman, Rida Fatima, Aymar AKILIMALI
Published: 29 December 2025
This article explores Fitusiran, a groundbreaking RNAi-based antithrombin-targeting therapy, marking a paradigm shift toward factor-independent prophylaxis in hemophilia management.
• Read here.
Honored to contribute to the evolving landscape of hemophilia therapeutics and RNA-based medicine.
Feedback and discussions are most welcome!”
Article: Rebalancing Hemostasis: Fitusiran as a First-in-Class RNAi Therapy in Hemophilia A and B
Authors: Raza Ur Rehman, Rida Fatima, Aymar Akilimali

Stay updated on all scientific advances with Hemostasis Today.
-
Nov 17, 2026, 14:10Wolfgang Miesbach: Aspirin vs Anticoagulants – Who Needs More Than Aspirin?
-
Nov 17, 2026, 14:08Chaza Alaji: Soluble Transferrin Receptor – A Key to Uncovering Hidden Iron Deficiency
-
Nov 17, 2026, 14:03Shadi Tabibian: Fibrinogen – From Molecular Structure to Clinical Decision Making
-
Nov 17, 2026, 13:54Gabrielle Sarlon: Breaking the Silence on Menstrual Bleeding During Anticoagulant Therapy
-
Nov 17, 2026, 13:47Ksenia Guznova Kats: Advanced Venous Stenting in May–Thurner Syndrome
-
Nov 17, 2026, 13:37Abdlemewla Ibrahim: Prasugrel vs Ticagrelor in ACS Patients Undergoing PCI
-
Nov 17, 2026, 13:30Stacy E. Croteau: Oral and Dental Care in Pediatric Patients With Bleeding Disorders
-
Nov 17, 2026, 13:19Efe Saglam: Cannabis Use and Cardiac Conduction
-
Nov 17, 2026, 10:41Elena Petkovic։ Highlights from the ISBT–WHO Plasma Management Workshop